We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Pharsight Launches Phoenix NLME™ for Model-Based Drug Development
Product News

Pharsight Launches Phoenix NLME™ for Model-Based Drug Development

Pharsight Launches Phoenix NLME™ for Model-Based Drug Development
Product News

Pharsight Launches Phoenix NLME™ for Model-Based Drug Development

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Pharsight Launches Phoenix NLME™ for Model-Based Drug Development"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Pharsight has announced the launch of Phoenix NLME (Nonlinear Mixed Effects), the next generation of the company’s data processing and modelling software for population pharmacokinetic and pharmacodynamic (PK/PD) analysis.

Phoenix NLME 1.0 replaces Pharsight’s WinNonMix® and joins Phoenix™ WinNonlin® and Phoenix Connect™ on the Phoenix™ platform, Pharsight's new desktop software environment that is designed to advance model-based drug development by providing an integrated environment for data analysis, modeling and simulation.

Major features of Phoenix NLME 1.0 include flexible tools to create models from an extensive built-in library of models, graphically, or via user-supplied code. For models built graphically, Phoenix NLME automatically writes the corresponding equations. Code-based models can be submitted through the program’s user interface or via batch mode. Phoenix NLME also provides support for model bootstrapping, posterior predictive checks and tools for comparison of model estimation runs.

Other notable features of Phoenix NLME include graphical workflows that integrate data preparation, model selection and generation of tables and figures, and parallelized model estimation engines designed to take advantage of significant speed gains available on modern computers running multiple processors. Phoenix NLME 1.0 can be optionally configured to connect with a drug development organization’s computer grids and clusters.

“Phoenix NLME shortens the learning curve for drug development scientists to make initial use of population modelling methods, and also provides high-end functionality required by more advanced modellers,” said Daniel Weiner, Ph.D., senior vice president and chief technology officer of Pharsight. “Phoenix NLME offers a powerful combination of population PK/PD analysis tools, estimation engines and model comparison features all available from within the unified Phoenix software environment that provides users with high-quality graphics, workflow management and interoperability with third-party modelling and simulation tools.”

Concurrent with the release of Phoenix NLME 1.0, Pharsight has released updated versions of Phoenix WinNonlin (version 6.1) and Phoenix Connect (version 1.1) software, both of which were launched in June 2009. Phoenix WinNonlin is the next generation of Pharsight’s industry standard software for PK/PD modeling and noncompartmental analysis.

Phoenix Connect integrates applications built on the Phoenix platform with commonly used third-party analysis and modeling tools such as NONMEM®, R®, SAS® and S-PLUS®. Phoenix Connect provides environment for running NONMEM, with management tools for NONMEM file creation, automatic post-processing of NONMEM output and a comparison module to assist in comparing results of multiple NONMEM models.

Phoenix NLME is optionally compatible with Phoenix WinNonlin, Phoenix Connect and Pharsight Knowledgebase Server™ (PKS™), the company’s enterprise data management system for secure storage and tracking of PK/PD data and analyses.

“The release of Phoenix NLME represents another important milestone in Pharsight’s vision for software to enable model-based drug development and its utility in translational science,” added Dr. Weiner.

“The Phoenix platform has been developed to provide a collaborative environment for drug development scientists and to shorten the learning curve to more complex and impactful modelling, which ultimately supports more confident and efficient clinical development decisions. We look forward to introducing the benefits of Phoenix NLME to our Phoenix WinNonlin and WinNonMix user bases and to other population modelling experts in the field.”